KOPRAN vs KREBSBIO: Stock Comparison

KOPRAN vs KREBS BIOCHEMICALS & INDUpdated 4 Sept 26, 4:08 PM ISTNSE & company filings

KOPRAN is the larger company by market capitalisation. KOPRAN shows a higher dividend yield, a higher ROCE and a higher net margin, while KREBS BIOCHEMICALS & IND shows a lower P/E and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Metric snapshot

KOPRAN leads 6; KREBSBIO leads 5 of 11

Not a rating

Interactive comparison

Compare the numbers that shape the decision

Every row uses its own scale. Switch lenses to compare like with like.

KOPRANKREBSBIO

Valuation lens

What price are you paying?

Market CapContext only
₹1,120 Cr
₹121 Cr
P/E RatioKREBSBIO has the lower reading
37.34x
0x
P/B RatioKREBSBIO has the lower reading
1.76x
0x
EPSKOPRAN has the higher reading
₹1.39
₹-1.15
Book ValueContext only
₹109.82
Dividend YieldKOPRAN has the higher reading
2.76%
0%

✓ marks the usual favourable reading; it is not a recommendation.

Key Differences

Market Cap
KOPRAN is the larger company
₹1,120 Cr vs ₹121 Cr
P/E Ratio
KREBSBIO has a lower P/E
0x vs 37.34x
P/B Ratio
KREBSBIO has a lower P/B
0x vs 1.76x
EPS
KOPRAN has higher earnings per share
₹1.39 vs ₹-1.15
Dividend Yield
KOPRAN has a higher dividend yield
2.76% vs 0%
Revenue Growth (TTM YoY)
KREBSBIO has faster revenue growth
11.6% vs -3.66%
EPS Growth (TTM YoY)
KREBSBIO has faster EPS growth
0% vs -71.88%
Qtr Sales Growth
KOPRAN has stronger quarterly sales growth
-59.25% vs -70.57%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricKOPRANKREBSBIO
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricKOPRANKREBSBIO
Live Price₹232.54₹55.95
Day Change0.13%2.66%
Volume6.61 L5,830
52-Week High₹239.6₹82.49
52-Week Low₹107₹38.33
Distance from 52W High-2.95%-32.17%

Valuation

MetricKOPRANKREBSBIO
Market Cap₹1,120 Cr₹121 Cr
P/E Ratio37.34x0x
P/B Ratio1.76x0x
EPS₹1.39₹-1.15
Book Value₹109.82
Dividend Yield2.76%0%

Growth

MetricKOPRANKREBSBIO
Revenue Growth (TTM YoY)-3.66%11.6%
EPS Growth (TTM YoY)-71.88%0%
Qtr Sales Growth-59.25%-70.57%
Qtr Profit Growth0.33%85.33%

Profitability & Leverage

MetricKOPRANKREBSBIO
ROE4.85%
ROCE4.89%-15.89%
Net Margin3.78%-71.35%
Operating Margin6.58%-41.49%
Debt to Equity0.29x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricKOPRANKREBSBIO
Promoter Holding44.42%72.74%
FII Holding0.51% 0.06 pp0.5%
DII Holding0%0%
Public Holding55.06% 0.06 pp26.76%

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: KOPRAN and KREBS BIOCHEMICALS & IND.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.